Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma

被引：0
|
作者：
Jordan Amdahl
Lei Chen
Thomas E. Delea
机构：
[1] Policy Analysis Inc. (PAI),
[2] Novartis Pharmaceuticals,undefined
来源：
Oncology and Therapy | 2016年 / 4卷 / 2期
关键词：
Clinical trials; Melanoma; Network meta-analysis;
D O I：
10.1007/s40487-016-0030-2
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：239 / 256
页数：17
相关论文
共 50 条
  • [21] Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer
    Galsky, Matt D.
    Krege, Susanne
    Lin, Chia-Chin
    Hahn, Noah M.
    Ecke, Thorsten
    Moshier, Erin L.
    Sonpavde, Guru
    Godbold, James H.
    Oh, William K.
    Bamias, Aristotelis
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [22] Meta-analysis for the Association between Overall Survival and Progression-Free Survival in Gastrointestinal Stromal Tumor
    Oezer-Stillman, Ipek
    Strand, Lauren
    Chang, Jane
    Mohamed, Ateesha F.
    Tranbarger-Freier, Katherine E.
    CLINICAL CANCER RESEARCH, 2015, 21 (02) : 295 - 302
  • [23] Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma
    Han, Kelong
    Ren, Melanie
    Wick, Wolfgang
    Abrey, Lauren
    Das, Asha
    Jin, Jin
    Reardon, David A.
    NEURO-ONCOLOGY, 2015, 17 (05) : 764 - 765
  • [24] PERSONALIZED DISCRETE EVENT SIMULATION OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL FOR FIRST-LINE DOUBLET CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER
    Degeling, K.
    Wong, H. L.
    Johns, J.
    Koffijberg, H.
    Gibbs, P.
    IJzerman, M.
    VALUE IN HEALTH, 2019, 22 : S96 - S96
  • [25] Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials
    Petrelli, Fausto
    Coinu, Andrea
    Borgonovo, Karen
    Cabiddu, Mary
    Barni, Sandro
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2015, 14 (02) : 124 - 131
  • [26] Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials
    Fausto Petrelli
    Andrea Coinu
    Karen Borgonovo
    Mary Cabiddu
    Sandro Barni
    Hepatobiliary & Pancreatic Diseases International, 2015, 14 (02) : 124 - 131
  • [27] BEVACIZUMABIN AND FIRST-LINE CHEMOTHERAPY IN THE TREATMENT OF METASTATIC COLORECTAL CANCER: EVALUATION OF CLINICAL EFFICACY AND PROGRESSION-FREE SURVIVAL
    Liang, Jinhao
    Xiang, Chengjiang
    Sun, Ke
    FARMACIA, 2023, 71 (04) : 747 - 754
  • [28] Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada
    Thomas E. Delea
    Jordan Amdahl
    Alice Wang
    Mayur M. Amonkar
    Marroon Thabane
    PharmacoEconomics, 2015, 33 : 367 - 380
  • [29] Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis
    Paoletti, Xavier
    Oba, Koji
    Bang, Yung-Jue
    Bleiberg, Harry
    Boku, Narikazu
    Bouche, Olivier
    Catalano, Paul
    Fuse, Nozomu
    Michiels, Stefan
    Moehler, Markus
    Morita, Satoshi
    Ohashi, Yasuo
    Ohtsu, Atsushi
    Roth, Arnaud
    Rougier, Philippe
    Sakamoto, Junichi
    Sargent, Daniel
    Sasako, Mitsuru
    Shitara, Kohei
    Thuss-Patience, Peter
    Van Cutsem, Eric
    Burzykowski, Tomasz
    Buyse, Marc
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (21): : 1667 - 1670
  • [30] Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada
    Delea, Thomas E.
    Amdahl, Jordan
    Wang, Alice
    Amonkar, Mayur M.
    Thabane, Marroon
    PHARMACOECONOMICS, 2015, 33 (04) : 367 - 380
12345